After reporting that an isoform of BTK (BTK-C) protects breast cancer cells from apoptosis in 2013 [36], in 2016, Wang et al. showed that inhibition of BTK by ibrutinib could decrease cancer cell survival and prevent drug resistance [37]. Here, BTK is linked to breast carcinoma.